Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Advanced Viral Research (OTC BB:ADVR.OB)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Insider | Financials
Location
200 Corporate Boulevard South
Yonkers, NY 10701
Phone: (914) 376-7383
Employees (last reported count): 35
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Related Links
 ·Search Yahoo! for related links...
Ownership
·Insider and 5%+ Owners: 28%
·Institutional: 0% (0% of float)
(5 institutions)
·Net Inst. Buying: 7,000  shares (+9.67%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Advanced Viral Research Corp. engages in the production and marketing, promotion and sale of the pharmaceutical drug, Reticulose, for the treatment of certain viral and autoimmune diseases such as human immunodeficiency virus (HIV), including acquired immune deficiency syndrome (AIDS); hepatitis B and hepatitis C liver diseases; human papilloma virus (HPV), which causes genital warts and may lead to cervical cancer, and rheumatoid arthritis. The Company's operations have been limited principally to research, testing and analysis of Reticulose in the United States, either in vitro (outside the living body in an artificial environment, such as in a test tube) or on animals, and engaging others to perform testing and analysis of Reticulose on human patients outside the United States. The Food and Drug Administration has not approved human clinical trials for Reticulose in the United States.
More from Market Guide: Expanded Business Description

Financial Summary
ADVR is engaged in the production and marketing, promotion and sale of a pharmaceutical drug with the trade name Reticulose. Reticulose has not yet been approved for sale or use by the FDA in any foreign government body. For the six months ended 6/30/01, net sales totalled $11 thousand, up from $5 thousand. Net loss rose 46% to $4.9 million. Revenues reflect an increase in distributor purchases of Reticulose. Higher loss reflects increased R&D expenses related to GloboMax.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Bernard Friedland, 75
Chairman
--  
Shalom Hirschman, M.D., 64
Pres, CEO, Director and Chief Scientific Officer
$396K
Alan Gallantar, 43
CFO
246K
William Bregman, 79
VP, Sec., Treasurer, Director
--  
Raymond Tudor
VP, Drug Devel.
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- OTC BB:ADVR.OBAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Nov-2000
$0.25 
Recent Price$0.35 
52-Week High
on 6-Sep-2000
$0.688
Beta0.91 
Daily Volume (3-month avg)691.1K
Daily Volume (10-day avg)642.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-36.0%
52-Week Change
relative to S&P500
-14.2%
Share-Related Items
Market Capitalization$134.7M
Shares Outstanding384.8M
Float277.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.01 
Earnings (ttm)-$0.03 
Earnings (mrq)-$0.01 
Sales (ttm)$
Cash (mrq)$0.00 
Valuation Ratios
Price/Book (mrq)36.78 
Price/EarningsN/A 
Price/Sales (ttm)9,714.05 
Income Statements
Sales (ttm)$14.0K
EBITDA (ttm)-$9.39M
Income available to common (ttm)-$10.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-184.36%
Return on Equity (ttm)-230.08%
Financial Strength
Current Ratio (mrq)1.22 
Debt/Equity (mrq)0.06 
Total Cash (mrq)$1.27M
Short Interest
Shares ShortN/A 
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.